Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Crescent Biopharma (CBIO) Other Operating Expenses (2024 - 2025)

Crescent Biopharma (CBIO) has disclosed Other Operating Expenses for 2 consecutive years, with $16.8 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses changed N/A to $16.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.8 million through Dec 2025, changed N/A year-over-year, with the annual reading at $1.2 million for FY2024, N/A changed from the prior year.
  • Other Operating Expenses for Q4 2025 was $16.8 million at Crescent Biopharma, up from $1.2 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $16.8 million in Q4 2025, with the low at $1.2 million in Q3 2024.